Idéal Investisseur
Français English
CAC 40 : Market open
7 846,22 pts
+0.17%


Last updated : 13/10/2026 - 13h32
🏠 Home   ➤    Stock news

Inventiva: the stock, among the steepest declines on the SBF 120, drops 14.5% in one month

The Burgundy biotech company specializing in fibrotic and metabolic diseases is losing ground at midday, while the SBF 120 advances slightly. The stock ranks at the bottom of the index and extends a correction phase that began several weeks ago. The movement follows a Paris market focused on French debt, with a 10-year OAT close to its highs.


Inventiva: the stock, among the steepest declines on the SBF 120, drops 14.5% in one month

A value moving away from its moving averages, three weeks after its low

The Inventiva stock loses 1.36% to €2.90, among the steepest declines on the SBF 120, while the index gains 0.28%. The decline reaches 14.71% over one month and 22.25% over three months, a drop that leaves the price far from its medium and long-term benchmarks: The 50-day MA at €3.60 is 19.44% above the price, with the 200-day MA at €4.26 standing 31.92% higher. The stock is also approaching its support level at €2.77, already at the center of the September 29 session. The RSI at 41 has returned to neutral territory, after the extreme oversold levels observed in late September, which leaves the price without marked buying momentum.

Strengthened cash position of €166.1 million, but no revenue in the half-year

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis

During the publication of H1 2026, on July 30, the company reported a cash position of €166.1 million as of June 30, resulting from the capital offering of €103 million and the financing operation of €75 million announced on June 2. No revenue was recorded in the half-year, compared with €4.5 million a year earlier, and the cash runway extends to the end of the second quarter of 2027 without additional financing. Tranche C of the financing operation could bring up to €20 million, and the exercise of warrants from tranche 3 up to €116 million.

Inventiva is listed on two markets: the ordinary share in Paris, eligible for the PEA, and the ADS on Nasdaq, at the rate of one share for one ADS. The next major milestone remains the primary results of the phase 3 NATiV3 study, which the company is preparing following its half-year review.



Sector Pharmacie et biotechnologies › Biotechnologies


Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext

Context

Period
  • Period: S1 2026
Key reported figures
  • Revenue: 0 millions d'euros
  • Quarterly revenue: 0 millions d'euros
  • Revenue growth: -100 %
  • Net income: -69,5 millions d'euros
  • Free cash flow: -48,7 millions d'euros
Risks mentioned
  • La trésorerie actuelle ne couvre pas les besoins opérationnels des 12 prochains mois.
  • Horizon de trésorerie limité à la fin du deuxième trimestre 2027 sans financements additionnels.
  • Aucun chiffre d'affaires enregistré au premier semestre 2026, contre 4,5 M€ un an plus tôt.
Opportunities identified
  • Offre Equity de 103 M€ et Opération de Financement de 75 M€ annoncées le 2 juin 2026.
  • Tranche C de l'Opération de Financement pouvant apporter jusqu'à 20,0 M€.
  • Exercice des warrants Tranche 3 pouvant générer jusqu'à 116,0 M€.

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours